Nicola Mason is a Professor in the Department of Clinical Sciences and Advanced Medicine at the University of Pennsylvania’s School of Veterinary Medicine. She received her veterinary degree from the Royal Veterinary College and her Immunology PhD from the University of Pennsylvania. She performed her post -doctoral fellowship at the Abramson Cancer Center at the School of Medicine at UPenn.

Dr. Mason’s translational research focuses on developing safe and effective immunotherapies for dogs with cancer. Through comparative medicine her work aims to accelerate the clinical implementation of effective immunotherapies into the human clinics. Dr. Mason leads the first canine cancer immunotherapy consortium, supported by the Biden Cancer Moonshot initiative. She is the principal investigator of the national study, performed through the Comparative Oncology Trials Consortium, to evaluate the effects of a live, recombinant HER2 targeting Listeria vaccine in dogs with osteosarcoma.